Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 11, 2019 08:30 ET | Source: Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics to Present Preclinical Data on its Clinical-Stage sGC Stimulators for Neurodegenerative and Cardiometabolic Diseases at the 9th International Conference on cGMP

– Series of preclinical studies provide further rationale for study of IW-6463 as a potential treatment for neurodegenerative diseases – – Preclinical data provide insights into...
June 04, 2019 08:30 ET | Source: Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics to Present Data on its Sickle Cell Disease Program at Upcoming Medical and Scientific Meetings

– In preclinical study, treatment with company’s investigational sGC stimulator olinciguat was associated with improved blood flow and reduced inflammation in a model of sickle cell disease – – New...
May 13, 2019 07:00 ET | Source: Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics Provides a Corporate and Pipeline Overview as a Newly Launched Public Biopharmaceutical Company

– Completed enrollment in Phase 2 studies of praliciguat in diabetic nephropathy and heart failure with preserved ejection fraction (HFpEF) – – Based on encouraging tolerability data, company intends...
April 25, 2019 08:00 ET | Source: Cyclerion Therapeutics, Inc.

Cyclerion to Host Corporate Overview Call on May 13, 2019

CAMBRIDGE, Mass., April 25, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase...
April 09, 2019 08:00 ET | Source: Cyclerion Therapeutics, Inc.

Cyclerion Announces the Appointment of Andreas Busch, Ph.D., as Chief Innovation Officer

CAMBRIDGE, Mass., April 09, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase...
April 02, 2019 08:00 ET | Source: Cyclerion Therapeutics, Inc.

Cyclerion Launches as Clinical-Stage Biopharmaceutical Company Harnessing the Power of Soluble Guanylate Cyclase (sGC) Pharmacology for Treatment of Serious and Orphan Diseases

– $175 million committed from investors in private placement offering – – Trading of CYCN begins on Nasdaq today – CAMBRIDGE, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics,...